Vesalius Biocapital related stories
All articles and analysis
Vesalius Biocapital collects €95m for fourth fundInvestors in Fund IV include the European Investment Fund.
Scenic Biotech rakes in $31m Series AScenic Biotech BV, a developer of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, has raised $31 million in Series A financing.
- BDC Capital, EDC invest in venture-backed Exact Imaging
Toronto-based Exact Imaging, a maker of micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, has raised C$5.1 million in financing.
Vesalius Biocapital raises €120mThe Luxembourg-headquartered specialist life sciences venture capital firm closes third fund.
Vesalius Biocapital wraps up third fundLuxembourg-based Vesalius Biocapital, a life sciences venture firm, has closed its third fund at 120 million euros. The fund's investors includes the European Investment Fund. Vesalius Biocapital III targets later-stage European life science companies in drug development, medtech, diagnostics and digital health.
- Vesalius Biocapital Fund III raises $72.3 mln in first close
Vesalius Biocapital said May 18 that a first close of its third fund has secured more than 65 million euros ($72.3 million) in commitment. Vesalius Biocapital III has a 150 million euro ($167 million) target. Vesalius Biocapital III will focus on later-stage European companies in drug development, medtech, diagnostics and eHealth / mHealth.
- Canadian VC begins 2017 strongly as top Q1 deals take $400 mln
Canada’s top 10 first-quarter venture-capital financings drew close to $400 million from investors. While that’s down 19 percent from the $490 million raised by the top 10 deals a year earlier, it far exceeds the first-quarter results of other recent years. The estimate is based on PE Hub Canada’s list of the largest financings announced from January through March, supplemented by Thomson Reuters data. The list is headed by PointClickCare, which accounted for 2017’s first deal sized above $100 million, Visier, Inocucor Technologies and Fusion Pharma.
Lumira, Vesalius co-lead Exact Imaging's $21.5 mln Series C roundToronto medical device startup Exact Imaging has secured $21.5 million in a Series C financing. The round was co-led by Canadian venture capital firm Lumira Capital and Luxembourg's Vesalius Biocapital with participation from new investors, including PMV, and existing investors, including iGan Partners. With the financing, Lumira's Peter van der Velden, PMV’s Dr. Alexandra Tolia and Vesalius' Dr. Gaston Matthyssens will join the board. Founded in 2013 by Sam Ifergan and Randy AuCoin, Exact develops micro-ultrasound technology that enables real-time imaging and biopsy guidance for the prostate. It plans to use the funds raised to commercialize its new ExactVu system.
- Promethera Biosciences pulls in $11 mln
Promethera Biosciences SA, a Belgian cell therapy and regenerative medicine company targeting liver diseases, has raised $11 million in funding. The investors included Vesalius Biocapital, SRIW, Boehringer Ingelheim Venture Fund, SMS Investments, Mitsubishi UFJ Capital Co. Ltd. and Cell Innovation Partners LP.